Targeted profiling of more than 100,000 cancers by Foundation Medicine suggests mutation-rich tumors occur quite frequently, perhaps opening the door to broader immunotherapy application.
Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.
The project aims to sequence the immune repertoires of study participants to spur new vaccine and immunotherapy development.
Cancer Genetics will help analyze biomarkers to identify response patient populations, as well as reflect the mechanism of action of Effector's eFT508.
CSO Phil Stephens said the firm is finding specific genomic alterations that appear to affect sensitivity to immunotherapies, as it also advances overall mutation burden testing.
The firms will use the FoundationOne assay to characterize tumors and their microenvironment to find predictive measures of response to cancer immunotherapies.
The firm's treatments are based on stimulating the innate immune system with drugs made from inactivated bacteria to restore normal immune function.
Samples from metastatic melanoma patients treated sequentially with immunotherapies targeting CTLA4 and PD-1 pointed to response-related tumor features.
Mutation and predicted neoantigen profiles for more than 63,000 tumors suggests it would be difficult to design a broadly beneficial cancer vaccine.
The firm will apply the proceeds towards an early-stage clinical trial of a precision colorectal cancer vaccine.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.